Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05707871 · ClinicalTrials.gov registry record · Early Phase 1

Cardiovascular Effects of Very Low Nicotine Content Cigarettes

A Early Phase 1 study of Tobacco Use, sponsored by Wake Forest University Health Sciences.

Recruiting
Registry status
Early Phase 1
Development phase
49
Enrollment target
1
Study location

NCT05707871 is a Early Phase 1 study of Tobacco Use that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 49 participants, below the 378-participant average among 76 other Tobacco Use trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05707871, a Early Phase 1 study of Tobacco Use, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.

RECRUITING
Registry status
Early Phase 1
Development phase
49 participants
Enrollment target
1
Study location

Study Summary

The study is measuring Cardiovascular effects of very low nicotine content cigarettes on daily and non-daily smokers

Conditions Studied

Interventions

  • DRUG SPECTRUM cigarettes
  • OTHER usual brand of Cigarettes

Study Locations (1)

North Carolina

  • Wake Forest University Health Sciences - Winston-Salem

Trial Details

FieldValue
Enrollment Target 49 participants
Start Date 2023-04-04
Est. Completion 2026-12
Phase Early Phase 1

Sponsor

Wake Forest University Health Sciences

1,140 total trials

What the Registry Record Tells You About NCT05707871

The ClinicalTrials.gov registry entry for NCT05707871 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 378-participant average among 76 other Tobacco Use trials with a reported enrollment target (87% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Tobacco Use appearing as the primary indexed condition, and to 2 interventions - of which SPECTRUM cigarettes is the first listed.

NCT05707871 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT05707871 about?

NCT05707871 is a clinical study titled "Cardiovascular Effects of Very Low Nicotine Content Cigarettes". The study is measuring Cardiovascular effects of very low nicotine content cigarettes on daily and non-daily smokers

What is the current status of trial NCT05707871?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 49 participants. The study started on 2023-04-04. Estimated completion is 2026-12.

What conditions does trial NCT05707871 study?

This clinical trial studies the following conditions: Tobacco Use.

What interventions are being tested in trial NCT05707871?

The interventions under investigation include: SPECTRUM cigarettes (DRUG), usual brand of Cigarettes (OTHER).

Who is sponsoring clinical trial NCT05707871?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05707871 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Tobacco Use

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.